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with n-HFL patients comparing the use of filgrastim after
peripheral blood progenitor cells reinfusion.
METHODS: Multi-centre study conducted in France be-
tween 1995-1999 including 51 patients (24 placebo (P)
and 27 filgrastim (FI)). Demographic, disease and treat-
ment-specific information was collected through the
CRF. QoL assessment per patient over 90 days of follow-
up (FU) was calculated as follows. QoL-index valued
from 0 (worst) to 1 (best) was used to assign QoL per
hospital day: in sterile room (SR)  0.6; in a normal
room (NR)  0.9. Each adverse event (AE) (WHO grade
3 or 4) affected the QoL index with an additional factor
of 0.8, 0.6, 0.4 or 0.2 respectively for 1, 2, 3, 	 4 con-
comitant AEs per patient per day. Average QoL-scores
over time per treatment arm were compared using Kaplan-
Meier statistics (p  .05, two-sided). Sensitivity analysis
on the score index over the FU was undertaken.
RESULTS: For FI the average days with 0, 1, 2, 3, 4
AEs in a SR was 6.59, 4, 2.56, 0.81, 0.37 and in a NR,
1.59, 1.67, 0.56, 0.11, 0. For P in a SR we had respec-
tively 8.3, 3.8, 2.8, 2.2, 0.125 and in a NR, 2.13, 0.9, 0,
0, 0. Average estimated QoL-score was 81.71 for FI (SD:
3.15, range: 72.54–85.24) and 80.66 for C (SD: 3.01,
range: 71.8–84.68) (Mann Witney U test: p  0.49 but
decreased to 0.25 for first hospitalization period). Kap-
lan-Meier graph demonstrates after day 16 a constant
QoL benefit for FI due to earlier hospital discharge (Log
rank test: 27.2; p  .001).
CONCLUSION: Filgrastim use 24 hours post-PBPC in
high dose treatment of n-HFL patients is associated with
QoL improvement due to earlier hospital discharge.
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OBJECTIVE: It is assumed that genetic testing for breast-
ovarian cancer predisposition in the context of peer-re-
viewed research protocols at academic centers offers pro-
tection against test-related distress. However, BRCA1/2
genetic testing under research protocols often implies a
significant time delay before the test result can be dis-
closed, which would not apply to commercially available
testing. Using data from our own research setting, we in-
vestigated whether delay in getting BRCA1/2 test results
was associated with participants’ distress.
METHODS: Participants were 128 women from 26
French Canadian kindred with a BRCA1/2 germline mu-
tation identified. Genetic counseling was provided in a
pre-test education session and a result disclosure session.
Of the women tested, 53 (41%) were found to be carriers
of the familial mutation and 75 (59%), non-carriers.
Mean age at enrollment (48.4 yrs 
 12.1) was similar for
the two groups. Test-related distress was assessed by the
Impact of Event Scale one month after result disclosure.
RESULTS: Time interval between blood sample for test-
ing and result disclosure varied considerably (range: 35
to 756 days), and was similar for carriers (mean  172 

120 days) and non-carriers (mean  174 
 174 days).
Among non-carriers, those given their result less than six
months following blood draw (n  48) tended to have
lower levels of test-related distress (mean  3.3 
 5.2)
than those who were told their result beyond 6 months (n 
27, mean  7.8 
 11.2, p  0.06). For carriers, test-
related distress did not differ according to whether they
were given their result less than six months (n  35,
mean  10.4 
 13.7) after the blood draw or later (n 
18, mean  9.8 
 12.2).
CONCLUSIONS: Consistent with others, these results
indicate that most women cope well with test informa-
tion in research settings with careful expert counseling.
Nevertheless, our findings among non-carriers suggest
that prompt disclosure of BRCA1/2 test results has po-
tential quality-of-life benefits.
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OBJECTIVE: The EORTC QLQ-C30 is one of the most
widely used QL measures in cancer clinical trials. This
study aimed to look at the psychometric properties of the
QLQ-C30 in 32 countries with a database of 9000 pa-
tients.
METHOD: All EORTC studies incorporating the EORTC
QLQ-30 were systematically selected for this study. In-
clusion criteria for trials were if the trial containing the
QLQ-C30 responses had been coded into the EORTC
database. One hundred fourteen EORTC studies were re-
viewed of which 52 met the criteria for being included in
the final analysis.
RESULTS: The majority of cancer patients were receiv-
ing palliative care for primary cancers including mela-
noma, prostate, head and neck, breast and lung cancers
and 90% of the patients were distributed over 10 out of
the 32 countries. At least one item of data was missing in
14 to 17% of patient questionnaires completed, though
the average percentage of missing items per patient
ranged from 1.1% to 1.5% Particular items relating to
Role Functioning and Financial Difficulties were the most
common items missing (3%). Factor analyses for all three
versions of the questionnaire are similar, though some
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difference has been found when examining individual
cancers. Inter-domain correlations in each of the three
versions of the QLQ-C30 were strongest in Role Func-
tioning, Pain and Global Health Status. Cronbach’s reli-
ability measure shows improved reliability in newer ver-
sions of the questionnaire, for example, the pain scale
increases from 0.82 to 0.86 from version 1 to version 3.
CONCLUSION: We believe this is one of the first studies
to examine the scales of all three versions of the QLQ-
C30 with a large sample across a large number of coun-
tries and cancer sites. We found that in general all three
versions of the QLQ-C30 have similar psychometric
structures, that the measure proves to a be a useful tool
to use within a clinical trial setting and that missing data
is continually reducing over time, indicating increasing
compliance among staff/patients.
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OBJECTIVE: Quality of life (QOL) is becoming an ac-
cepted endpoint in cancer clinical trials. However, reports
suggest that fewer than 10% of clinical trials include QOL
assessment, it is believed that such reports may be biased
by time lag. This paper examines the extent of QOL stud-
ies that are conducted within one of the largest academic
cancer clinical trial organizations in Europe.
METHOD: Examination of all clinical trials conducted
by the EORTC (between 1990 to 2000) was undertaken
by reviewing databases, records and publications. Trials
were systematically selected if they involved any aspect of
QOL assessment. The protocols were then evaluated us-
ing criteria that evaluated the quality of trial designs and
methodology employed.
RESULTS: In total, 112 clinical trials involving over 10,000
patients were identified as having a QOL component. All
trials involved multinational patient recruitment, with the
highest recruitment from the Netherlands, France and Ger-
many, and lowest from Malta, Estonia and Slovakia. Ap-
proximately 25 disease groups have been actively recruiting
patients from disease groups of genito-urinary, breast and
lung cancers. A clear linear trend was noted, with increasing
numbers of clinical trials involving QOL components over
this period. Of these trials, 74 studies were Phase III, 15
Phase II and the remainder were feasibility studies. Pres-
ently, 45 trials are ongoing, 19 almost ready for data analy-
sis, 15 published and 10 being analyzed. In the last year, 30
studies involving QOL assessment have been submitted for
research, suggesting that QOL is a highly important end-
point in trials throughout Europe
CONCLUSION: While a decade ago QOL was not a ma-
jor component of EORTC clinical trials, it is now highly
integrated into trials, almost a standard secondary end-
point. In the European context, this suggests that clini-
cians and researchers are increasingly seeing the impor-
tance of patient-based outcome assessment methods.
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OBJECTIVE: Recommendations on the appropriate use
of corticosteroids (cort) and HT-3 antagonists (HT3A),
alone or in combination with benzodiazepines (benz) and
dopamine receptor antagonists (dopA) vary between
three and nine different anti-emetic strategies.
METHODS: We retrospectively compared the use of
anti-emetics in our clinical practice with the consensus
recommendations of Peruggia. We analyzed all patients
from a single department unit receiving chemotherapy on
an inpatient basis in February 2000.
RESULTS: One hundred thirty five days of chemother-
apy in 38 patients (20–78 years old, male/female 1,7/1)
suffering from various malignant diseases were included.
Five patients (13.1%) received anti-emetic therapy for
other reasons than preventing nausea and vomiting (e.g.
corticosteroids as comedication with paclitaxel). We
grouped the chemotherapy protocols as follows: very low
risk, (n  5); low risk, (n  44); moderate risk, (n  16);
high risk, (n  40); and severe risk, (n  30), according
to the Peruggia guidelines. We calculated the total theo-
retical consensus-guided costs for anti-emetic treatment
to be 2079.04 Deutsche Marks (DM) and the real costs
to be 2024.93 DM (hospital supplier prices).
CONCLUSION: We found a considerable drug-group-
related difference between consensus guidelines for anti-
emetic strategies and clinical practice. However, the total
expenditures did not vary significantly. We assume, that
the differences observed are due to patient-related factors
like history of nausea and emesis, tumor stage, tumor lo-
cation, sex, age, co-morbidity and alcohol consumption
rather than to chemotherapy. A computer-assisted anti-
emetic decision model (Emeto-Help) will be presented,
which includes both the drug-related emetogenic poten-
tial and the individual patient’s risk.
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